In the European Union (EU) Member States, QDENGA is indicated for the prevention of dengue disease in individuals from four years of age and should be administered subcutaneously as a 0.5 mL dose at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback